Everything you need to make the right decisions
Providing the most comprehensive and up-to-date information and analysis of the Medicated Skincare market, its consumers and the major players who make up that market.
Point of sale market data
In conjunction with IRi, extensive point of sale data shows you what consumers are spending their money on
How big is the market today and what is our 5 year forecast? Includes both best & worst case scenarios
What are the different segments within the market and how are those individual segments performing?
What are consumers looking for, what drives their buying habits and what are their main purchase influencers?
From iGen & Millennials to Baby Boomers & beyond. Who is spending money and what are they spending it on?
We gather our data from real-world consumers, selected to accurately reflect precise global demographics
What are the key players doing, what has been successful for them and what was their marketing spend?
Using data from our Global New Product Database, what products were launched and how well were they perceived?
What happens next, which areas are likely to experience growth and what opportunities exist within the market?
Expert analysis from a specialist in the field
Written by Jamie Rosenberg, a leading analyst in the Personal Care sector, his extensive knowledge delivers in-depth commentary and analysis to highlight current trends and add expert context to the numbers.
The medicated skincare market grew by 0.4% in 2017 and will reach an estimated $1.1 billion in 2018; an increase of just $14 million. Through 2023, Mintel estimates that the market will add between 1% and 3% per annum. Better prevention, oral medications, and non-medicated products will continue to challenge the category.
Senior Global Analyst, Household & Personal Care
Mintel has the answers you’re looking for
What are the key challenges facing the industry and how fast are its rates of growth? Who is the consumer and what do they want? Where are the opportunities, where are the risks and what lies ahead?
For the purposes of this Report, Mintel has used the following
Medicated skincare covers OTC (over-the-counter) products that
consumers use to treat skin irritations. Following is a list of the
specific product types and conditions that are addressed in this
report and the conditions that these products treat.
- Anti-itch creams/treatments – itching of the skin caused by
dry skin, cracked skin, eczema, psoriasis, poisonous plants, jock
itch, ringworm, skin rashes, bug bites, and other causes; insect
first aid products are included in this segment.
- Lip treatments – cold sore treatments.
- Skin growth removers – common warts (hand), plantar (foot),
and flat warts (clusters). Does not include genital warts.
Exluded are products for foot ailments, prescription medications
or OTC products that are taken orally to treat these conditions (for
example, non-prescription antihistamine tablets taken orally to treat
skin rashes or irritations). Products with medicated ingredients or
additions (eg bandages with antibiotic ointment added to the pad)
and lice treatments are also excluded from this Report.
What you need to know
The medicated skincare market grew by 0.4% in 2017 and will reach
an estimated $1.1 billion in 2018; an increase of just $14 million.
Through 2023, Mintel estimates that the market will add between
1% and 3% per annum. Better prevention, oral medications, and
non-medicated products will continue to challenge the category.
Yet, there are opportunities. Multifunctional products, fast-acting
cold sore and skin growth removers and ancillary products that help
consumers avoid the triggers of skin ailments will allow forward
looking brands to reinvent their portfolios for an evolving market.